The operating activities of the Merck Group are organized into four divisions. The Merck Serono division develops, manufactures and markets prescription medicines to treat cardiovascular diseases, cancer, neurodegenerative diseases, infertility, and selected metabolic disorders. More than 60% of Merck Serono’s sales are generated with biologics, making the division one of Europe’s leading suppliers of biopharmaceuticals. In the first quarter of 2013, Merck Serono accounted for around 55% of Group sales.
The Consumer Health division manufactures and markets over-the-counter pharmaceuticals that primarily address health themes such as mobility, women’s and children’s health, cough and cough as well as everyday health protection. This division’s contribution to Group sales was about 4% in the first quarter of 2013.
With its Performance Materials division, Merck is the market leader in liquid crystal mixtures for liquid crystal displays (LCD) as well as in special effect pigments for decorative applications, e.g. in automotive coatings and the cosmetics industry. The division generated around 16% of Group sales in the first quarter of 2013.
Within its relevant market segments, the Merck Millipore division is one of the top three suppliers of tools for the life science industry, marketing and developing solutions to support the academic, pharmaceutical and biopharmaceutical and chemical industries to increase productivity in laboratories as well as to ensure quality, increase yields and lower costs in drug production. Reflecting the industry-specific needs of its customers, Merck Millipore has three business units: Bioscience and Lab Solutions, which both primarily serve the needs of researchers and laboratories, and Process Solutions, which supplies products used primarily for clinical and commercial-scale pharmaceutical production. In the first quarter of 2013, the division generated 25% of Group sales.
Merck Group | Sales by division – Q1 2013

| XLS |
|
Merck Group | EBITDA pre one-time items by division – Q1 | |||
|
|
|
|
|
|
|
|
|
|
|
€ million |
Q1 – 2013 |
Q1 – 2012 |
Change |
|
Merck Serono |
462.7 |
403.0 |
14.8% |
|
Consumer Health |
14.3 |
9.4 |
52.6% |
|
Performance Materials |
207.4 |
163.4 |
27.0% |
|
Merck Millipore |
161.9 |
166.0 |
–2.5% |
|
Corporate and Other |
–45.3 |
–67.4 |
–32.8% |
